Welcome to our dedicated page for Aveanna Healthcare Holdings SEC filings (Ticker: AVAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicaid reimbursement tables, nurse staffing costs, and three distinct business lines make Aveanna Healthcare’s disclosures some of the most intricate in home care. Finding where the 10-K explains pediatric private-duty margins or tracing insider sales before rate-change news can feel overwhelming.
Stock Titan solves this complexity. Our AI reads every Aveanna Healthcare SEC filing the moment it hits EDGAR, then delivers plain-English highlights. Whether you are searching for Aveanna Healthcare insider trading Form 4 transactions, need the latest Aveanna Healthcare quarterly earnings report 10-Q filing, or want Aveanna Healthcare SEC filings explained simply, we surface the numbers and context in seconds.
Here’s how investors use the platform:
- Track Aveanna Healthcare Form 4 insider transactions real-time to see executive buys and sells alongside AI-flagged sentiment.
- Compare segment trends with an Aveanna Healthcare earnings report filing analysis that links revenue shifts to staffing metrics pulled from 10-Qs.
- Dive into risks in the Aveanna Healthcare annual report 10-K simplified view—Medicaid rate exposure, labor pressure, and cash-flow notes all summarized.
- Review governance details through the Aveanna Healthcare proxy statement executive compensation snapshot.
- Receive alerts when an Aveanna Healthcare 8-K material events explained filing announces acquisitions, credit amendments, or leadership changes.
Stop scrolling through hundreds of pages. With understanding Aveanna Healthcare SEC documents with AI, you gain immediate clarity, real-time filing updates, and the confidence to act on complete information.
Aveanna Healthcare Holdings (AVAH) filed an 8-K announcing a Second Amendment to its Amended and Restated Stockholders Agreement and a Board change. The amendment limits executive stock transfers: any sale or transfer of common shares by covered executives requires prior approval by the Compensation Committee and must keep each executive in compliance with the Company’s Stock Ownership Guidelines. “Sell to cover” transactions for exercise price or tax withholding are exempt. The amendment also permits certain Other Stockholders to transfer shares without restriction or consent.
Separately, Christopher Gordon resigned as a Class II director, stating no disagreement with the Company. The Board appointed Sam Weil (age 35), a Bain Capital Principal, as a Class II director and member of the Compensation Committee, serving until the 2026 Annual Meeting. The Board determined he is independent under SEC and Nasdaq rules, and as a Bain affiliate he will not receive director compensation.
Aveanna Healthcare Holdings Inc. (AVAH) furnished an investor presentation under Regulation FD. On November 7, 2025, the company made a financial presentation available to investors, attached as Exhibit 99.1 to an 8‑K.
The materials are also posted in the Investors section of aveanna.com. The company states it uses its website to distribute important and time‑critical information. The information in Item 7.01, including Exhibit 99.1, is furnished and not filed, and is not subject to Section 18 liabilities or incorporated by reference unless specifically stated.
Aveanna Healthcare Holdings (AVAH) reported stronger quarterly results for the period ended September 27, 2025. Revenue reached $621.9 million, up from $509.0 million a year ago, and operating income rose to $53.6 million. Net income was $14.1 million (basic EPS $0.07; diluted $0.06), compared with a loss last year. For the nine-month period, revenue was $1.77 billion and net income was $46.3 million.
Liquidity and balance sheet improved. Cash from operations was $76.1 million for the nine months, ending cash at $145.9 million. Stockholders’ equity turned positive to $9.2 million from a deficit at year-end 2024. The company refinanced into $1,325.0 million of term loans maturing in 2032 at a 7.89% rate, repaid the $415.0 million second lien loan, and recorded a $5.9 million loss on extinguishment and $16.0 million debt modification expense.
Strategic actions and funding. Aveanna closed the Thrive Skilled Pediatric Care acquisition with total consideration of $75.7 million, including 11.2 million shares valued at $59.8 million and preliminary goodwill of $61.8 million. The receivables Securitization Facility balance was $165.0 million at a 7.00% rate, with the maximum increased to $275.0 million. Shares outstanding were 208,911,373 as of September 27, 2025.
Aveanna Healthcare Holdings Inc. (AVAH) furnished an 8-K announcing it issued a press release with financial results for the three and nine-month periods ended September 27, 2025. The press release is provided as Exhibit 99.1 and relates to Item 2.02 (Results of Operations and Financial Condition), with related information also referenced under Item 7.01 (Regulation FD).
The company states the information in this report, including Exhibit 99.1, is “furnished” and not “filed,” which means it is not subject to Section 18 liabilities and will only be incorporated by reference in other filings if specifically stated. The filing is signed by the Chief Accounting Officer as of November 6, 2025.
Aveanna Healthcare (AVAH) — Form 4 insider transaction: On 10/24/2025, Director and 10% Owner Paul R. Vigano reported sales by affiliated entities pursuant to the option to purchase additional shares in an underwritten secondary offering. J.H. Whitney VII, L.P. sold 1,251,909 shares at $9; JHW Iliad Holdings LLC sold 224,553 shares at $9; and JHW Iliad Holdings II LLC sold 23,538 shares at $9.
Following these trades, reported indirect holdings include 19,292,787 shares via J.H. Whitney VII, L.P.; 15,523,809 via PSA Healthcare Investment Holdings LLC; 3,460,515 via JHW Iliad Holdings LLC; 1,426,034 via PSA Iliad Holdings LLC; and 362,746 via JHW Iliad Holdings II LLC.
Aveanna Healthcare Holdings (AVAH) insider transaction: On October 24, 2025, J.H. Whitney VII, L.P. reported the sale of 1,251,909 shares of common stock at $9.00 per share, coded "S", executed in an underwritten secondary offering.
Following the transaction, beneficial holdings reported include 19,292,787 shares indirectly through J.H. Whitney VII, L.P.; 15,523,809 shares indirectly through PSA Healthcare Investment Holdings LLC; and 1,426,034 shares indirectly through PSA Iliad Holdings LLC. The filing notes that certain affiliated entities may be deemed to share voting and dispositive power over these shares, with customary disclaimers of beneficial ownership beyond pecuniary interest.
Aveanna Healthcare (AVAH): insider sale reported. A 10% owner affiliated with J.H. Whitney disclosed sales on 10/24/2025 at $9 per share pursuant to the option to purchase additional shares in an underwritten secondary offering. J.H. Whitney VII, L.P. sold 1,251,909 shares; JHW Iliad Holdings LLC sold 224,553 shares; JHW Iliad Holdings II LLC sold 23,538 shares.
Following these transactions, reported indirect beneficial holdings included 19,292,787 shares by J.H. Whitney VII, L.P., 3,460,515 shares by JHW Iliad Holdings LLC, and 362,746 shares by JHW Iliad Holdings II LLC. Additional affiliated entities reported holdings as disclosed.
Aveanna Healthcare Holdings Inc. (AVAH)10,000,000 shares of common stock at $9.00 per share. The underwriters were led by Jefferies and J.P. Morgan, and the transaction closed on October 23, 2025.
The selling stockholders also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares. Aveanna did not issue any shares in this sale and did not receive proceeds, as all shares were sold by existing holders.
Aveanna Healthcare (AVAH): Form 4 discloses secondary sales by affiliated holders. On October 21, 2025, entities affiliated with the reporting person sold Aveanna common stock in an underwritten secondary offering at $9 per share. The disclosed sales included 8,346,059 shares by J.H. Whitney VII, L.P., 1,497,018 shares by JHW Iliad Holdings LLC, and 156,923 shares by JHW Iliad Holdings II LLC.
Following these transactions, the filing lists beneficial ownership positions such as 20,544,696 shares for J.H. Whitney VII, L.P., 15,523,809 shares for PSA Healthcare Investment Holdings LLC, 3,685,068 shares for JHW Iliad Holdings LLC, and 386,284 shares for JHW Iliad Holdings II LLC.
Aveanna Healthcare Holdings (AVAH) reported insider transactions on a Form 4 tied to an underwritten secondary sale by J.H. Whitney–affiliated entities on October 21, 2025. Reported sales included 8,346,059 shares by J.H. Whitney VII, L.P., 1,497,018 shares by JHW Iliad Holdings LLC, and 156,923 shares by JHW Iliad Holdings II LLC, each at $9 per share.
Following the transactions, reported indirect beneficial holdings included 20,544,696 shares for J.H. Whitney VII, L.P., 3,685,068 shares for JHW Iliad Holdings LLC, and 386,284 shares for JHW Iliad Holdings II LLC. Additional reported indirect holdings showed 15,523,809 shares by PSA Healthcare Investment Holdings LLC and 1,426,034 shares by PSA Iliad Holdings LLC.
FAQ
What is the current stock price of Aveanna Healthcare Holdings (AVAH)?
What is the market cap of Aveanna Healthcare Holdings (AVAH)?
